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Acquired immunodeficiency syndrome (AIDS) was first 
reported in 1981 [1]. Five healthy young men suddenly 
presented with opportunistic pneumonia caused by Pneu-
mocystis carinii (currently termed P. jirovecii). The original 
report from Los Angeles was followed by many reports of 
patients with similar symptoms in large cities in North 
America and in Europe. People in resource-rich countries 
were shocked by this sudden emergence of a highly fatal 
disease among gay men. Two years later, a brand new ret-
rovirus was isolated [2]. The virus turned out to be the 
causal agent of AIDS and was named as the human immu-
nodeficiency virus (HIV). The typical natural course of an 
HIV infection is characterized by three major phases, i.e., 
acute phase, chronic asymptomatic phase and AIDS phase 
with severe immunodeficiency. In the acute phase, about 
half of the patients present with an acute viral syndrome 
(fever, skin rash, lymphadenopathy, etc.) a few weeks after 
the infection. The other half may stay asymptomatic. Pa-
tients shift from acute to chronic asymptomatic phase a few 
months following the initial infection. Although the chronic 
asymptomatic phase lasts for 8 to 10 years on average, the 
disease progression varies greatly from individual to indi-
vidual. AIDS is the terminal phase of an HIV infection and 
characterized with the prevalence of opportunistic diseases. 
HIV resides in body fluids, including blood, seminal flu-
id, and vaginal fluid. Sexual intercourse, and intravenous 
drug use are the main transmission routes. Mother-to-child 
transmission also occurs. HIV tends to spread among mi-
norities such as intravenous drug users, female commercial 
sex workers, and men who have sex with men (MSM). Ac-
cording to the estimation at the end of 2013 by World 
Health Organization (WHO), around 78 million people 
globally have become infected with HIV since the start of 
the epidemic and 39 million died of AIDS-related illnesses. 
Thirty-five million people were living with HIV/AIDS in 
2013: 24.7 million (70%) in Sub-Saharan Africa and 4.8 
million (14%) in Asia.  
In Asia, the first outbreak of HIV occurred in countries 
such as Thailand, Cambodia and Myanmar in late 1980s. 
Bordering Myanmar, Lao and Vietnam, the first cluster of 
146 cases in Yunnan province was reported in 1989 from 
Ruili, a beautiful city at the west corner of Dehong prefec-
ture facing Myanmar. By 2006, 48,951 cases were reported 
in Yunnan [3]. Circulating Recombinant Forms (CRFs) 
between subtype B and C HIVs were prevailing in the epi-
demic. Subtype B had been circulating among drug users in 
Northern Thailand, while subtype C had spread from 
Southern Africa to India and Myanmar. The recombination 
of the two HIV subtypes could have occurred in Yunnan. 
Following the economic expansion of China, the virus 
spread from Yunnan to coastal provinces such as Guangxi, 
Guangdong and even to Taiwan in 2004. The virus spread 
also to inland provinces such as Xinjiang and Sichuan [3]. 
Owing to the countermeasures at the country, province, 
prefecture and county levels, annual reported case numbers 
in Yunnan have leveled off, however the epidemic is still 
growing across the country. The province reporting the 
highest number of HIV infection changed over from Yun- 
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nan to Guangxi in 2011. From 1989 to 2014, 102,510 
HIV/AIDS cases have been reported cumulatively in Yun-
nan where the disease burden is still the highest in China. 
Forty-five percent of HIV cases reported in China by the end 
of 2014 were from Yunnan, Guangxi and Sichuan. 
Along with the economic expansion, HIV transmission 
routes are becoming more diverse and complex in China. 
Traditionally, intravenous drug use in Yunnan and plasma 
donation in Henan and surrounding provinces were main 
transmission routes in China [4]. However, transmission 
through commercial sex workers and homosexual activity 
has been contributed more to the expansion of the epidemic. 
In Yunnan, the most frequent transmission route switched 
from intravenous drug use to sexual intercourse around 
2006. In 2013, sexual intercourse was reported to be the 
route of transmission in 86% of 10,553 cases.  
The drug development for HIV started soon after the 
discovery of the virus. The first effective drug, zidovudine 
(AZT), a nucleoside reverse transcriptase inhibitor (NRTI) 
was approved for clinical use to treat HIV infected patients 
in 1987. Development of other NRTIs such as didanosine 
(ddI), zalcitabine (ddC), stavudine (d4T), lamivudine (3TC) 
followed by the early 1990s. Protease inhibitors such as 
saquinavir, ritonavir, indinavir, and nonnucleoside reverse 
transcriptase inhibitor (NNRTI), nevirapine, were approved 
in the mid-1990s. Combination anti-retroviral therapy 
(cART) combining three active drugs became available 
around 1995–1996 in the resource-rich countries. In the 
early days of cART, patients had to take many pills in a day 
with dietary restrictions and suffered from many adverse 
events, but new drug discoveries and the invention of fixed 
dose combos (two or more active drugs in a single tablet) 
have made cART safe and simple in resource-rich countries. 
Furthermore, newer classes of antiretroviral drugs such as 
integrase inhibitors and fusion inhibitors have been ap-
proved and used in clinical practice.  
Effective cART was also proven to be very important for 
HIV prevention [5]. Although China’s National Free An-
tiretroviral Treatment Program started in 2002, much im-
provement is still needed [6].  
As noted above, HIV infection tends to spread in large 
cities irrespective of the economic state of the country, pre-
sumably because of the large population, anonymity, etc. 
Yunnan is a vast but less densely populated province with 
many small villages located on the hills and mountains. It is  
hard to imagine a heavy HIV epidemic while you are driv-
ing in the province. This geography may contribute to the 
distribution of HIV, which occurs in a scattered manner. 
Higher numbers have been reported from prefectures on the 
highways radiating from Kunming such as Dehong (Ruili, 
Yingjiang), Honghe (Kaiyuan, Hekou) and Lincang 
(Cangyuan, Gengma). Scattered epidemics are there also in 
small villages. Cangyuan and Gengma have reported the 
highest prevalence in Lincang prefecture. In two admin-
istration villages there, the recent HIV prevalence was rec-
orded at about 4% of the population. 
Many small villages are located far away from the mod-
ern medical facilities. HIV-positive villagers need to travel 
a long way to obtain a physical examination and cART. It 
would be hard for them to be adherent to treatment even if 
the government provided free cART. Hence, HIV preven-
tion should be imperative. Scientific research on the spread 
of this virus should be a necessary component in measures 
taken to better understand and cope with these newly 
emerging HIV epidemics in these small villages. Molecular 
virology research would provide crucial information needed 
for developing the best prevention. 
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